Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/83770
The International Society of DNA Vaccines Presents 20th Anniversary Meeting The 21st Century Vaccine Technology: Expanding Research Horizons and Pathways to Product Licensure December 5 – 7, 2012 | Loews Coronado Bay Resort, San Diego, CA CALL FOR ABSTRACTS Authors wishing to contribute papers for selection as either posters or oral presentations to DNA Vaccines 2012 must submit a 300-word abstract for review by the program committee. Scope Abstract submissions are invited on all aspects of DNA vaccine technology. Basic research studies, improved formulation, improved delivery, adjuvants, novel constructs, prime-boost studies, and invivo-targeting strategies are encouraged. Also encouraged are reports focusing on infectious disease targets, cancer vaccines, and immunotherapeutics for human and animal health. Research focused on novel delivery of therapeutic agents using nucleic acids for the treatment of human or animal health is also encouraged. Clinical studies of nucleic acid strategies for vaccine immunotherapy and therapeutic modulation including RNA technologies are appropriate. Papers highlighting advances in vaccine monitoring and immune analysis including cutting- edge antibody and T-cell response assays are sought. In addition, presentations focused on vaccine trial design strategies as they pertain to the further development of genetic vaccines are encouraged. Papers describing new methods for manufacturing, production, monitoring, or delivery of DNA or RNA products are encouraged. Reports updating progress in clinical studies of nucleic acid vaccine technologies are encouraged. General Policy Abstracts must be submitted by September 10, 2012 (Late Breaker Deadline: October 10, 2012) with a $50.00 processing fee. All abstracts will be reviewed by the DNA Vaccines 2012 program committee, and a notice of acceptance or rejection will be emailed to the presenting author. The program committee of DNA Vaccines 2012 reserves the right to accept or refuse an abstract. Acceptance will be based on originality and no abstracts presented or published prior to DNA Vaccines 2012 meeting should be submitted. Instructions for oral/poster presentation will be sent to presenting authors of the accepted abstracts. Presenting authors must register and pay the registration fees in order to give their presentations at the meeting. Contact Sara McCarthy smccarthy@bioconferences.com 914-740-2100 MEDIA SPONSORS t AIDS Research and Human Retroviruses t Cancer Biotherapy & Radiopharmaceuticals t DNA and Cell Biology t Genetic Testing and Molecular Biomarkers t Human Gene Therapy and Part B: Methods t Journal of Interferon & Cytokine Research t Lymphatic Research and Biology t Nucleic Acid Therapeutics t OMICS: A Journal of Integrative Biology t Viral Immunology www.bioconferences.com/dna